A Prospective, Open-Label, Single-Arm, Single-Center Study To Assess The Pharmacokinetics/Pharmacodynamics (PK/PD) And Safety Of Different Cangrelor Doses In Neonatal Subjects At Risk Of Thrombosis
Phase of Trial: Phase I
Latest Information Update: 14 Apr 2017
At a glance
- Drugs Cangrelor (Primary)
- Indications Coronary thrombosis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Chiesi USA
- 10 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Jan 2018.
- 10 Apr 2017 Planned primary completion date changed from 1 May 2017 to 1 Jan 2018.
- 10 Apr 2017 Status changed from not yet recruiting to recruiting.